Dr. Iris Isufi, MD
Claim this profileYale Cancer Center
Studies Lymphoma
Studies B-Cell Lymphoma
9 reported clinical trials
18 drugs studied
Area of expertise
1Lymphoma
CD30 positive
CCND1 positive
t(11;14) positive
2B-Cell Lymphoma
CCND1 positive
t(11;14) positive
Affiliated Hospitals
Clinical Trials Iris Isufi, MD is currently running
GM T Cell Therapy Long-Term Follow-Up
for Cancer
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one GM T cell infusion will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Recruiting1 award Phase 2 & 3
Rituximab + Stem Cell Transplant
for Mantle Cell Lymphoma
This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma.
Recruiting2 awards Phase 3
More about Iris Isufi, MD
Clinical Trial Related7 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Iris Isufi, MD has experience with
- Autologous Hematopoietic Stem Cell Transplantation
- Ibrutinib
- Ifosfamide
- Etoposide
- Carboplatin
- Nivolumab
Breakdown of trials Iris Isufi, MD has run
Lymphoma
B-Cell Lymphoma
Mantle Cell Lymphoma
Acute Myeloid Leukemia
Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Iris Isufi, MD specialize in?
Iris Isufi, MD focuses on Lymphoma and B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved CD30 positive patients, or patients who are CCND1 positive.
Is Iris Isufi, MD currently recruiting for clinical trials?
Yes, Iris Isufi, MD is currently recruiting for 3 clinical trials in New Haven Connecticut. If you're interested in participating, you should apply.
Are there any treatments that Iris Isufi, MD has studied deeply?
Yes, Iris Isufi, MD has studied treatments such as Autologous Hematopoietic Stem Cell Transplantation, Ibrutinib, Ifosfamide.
What is the best way to schedule an appointment with Iris Isufi, MD?
Apply for one of the trials that Iris Isufi, MD is conducting.
What is the office address of Iris Isufi, MD?
The office of Iris Isufi, MD is located at: Yale Cancer Center, New Haven, Connecticut 06520 United States. This is the address for their practice at the Yale Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.